The cobas EGFR Mutation Test v2 is a real-time PCR test for the qualitative detection of EGFR exon 19 deletions, L858R and T790M mutations, and is used to determine which NSCLC patients are eligible for treatment with erlotinib or osimertinib. Here, EGFR is linked to non-small cell lung carcinoma.